Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Summary

This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.

Timeline

Start

2008-07

Primary completion

2012-01

Completion

2012-01

Drugs

Indications